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Abstract
Background: The aim of the trial is to demonstrate that with the use of modern IMRT/IGRT and reduction of safety
margins postoperative wound complications can be reduced.
Methods/ Design: The trial is designed as a prospective, monocentric clinical phase II trial. The treatment is
performed with helical IMRT on the Tomotherapy HiArt System© or with RapidArc© IMRT as available. All
treatments are performed with 6 MV photons and daily online CT-based IGRT.
A dose of 50 Gy in 2 Gy single fractions (5 fractions per week) is prescribed. Restaging including MRI of the
primary tumor site as well as CT of the thorax/abdomen is planned 4 weeks after RT. PET-examinations or any
other imaging can be performed as required clinically. In cases of R1 resection, brachytherapy is anticipated in
the 2nd postoperative week. Brachytherapy catheters are implanted into the tumor bed depending on the size
and location of the lesion. Surgery is planned 5–6 weeks after completion of neoadjuvant RT. All patients are
seen for a first follow-up visit 2 weeks after wound healing is completed, thereafter every 3 months during the
first 2 years. The endpoints of the study are evaluated in detail during the first (2 weeks) and second (3 months)
follow-up. Functional outcome and QOL are documented prior to treatment and at year 1 and 2. Treatment
response and efficacy will be scored according to the RECIST 1.1 criteria. A total patient number of 50 with an
expected 20 % rate of wound complications were calculated for the study, which translates into a 95 %
confidence interval of 10.0-33.7 % for wound complication rate in a binomial distribution.
Discussion: The present study protocol prospectively evaluates the use of IMRT/IGRT for neoadjuvant RT in
patients with soft tissue sarcomas of the extremity with the primary endpoint wound complications, which is the
major concern with this treatment sequence. Besides complications rates, local control rates and survival rates, as
well as QOL, functional outcome and treatment response parameters (imaging and pathology) are part of the
protocol. The data of the present PREMISS study will enhance the current literature and support the hypothesis
that neoadjuvant RT with IMRT/IGRT offers an excellent risk-benefit ratio in this patient population.
Trial registration: NCT01552239
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Background
Treatment of soft tissue sarcomas of the extremities is
a challenge for the interdisciplinary team. In general,
radiation therapy (RT) is indicated in stage II and III
(not T1a). There are two approaches for RT in this situ-
ation, either neoadjuvant or adjuvant. For preoperative
RT usually lower doses are applied, and a dose of 50 Gy
has been established; in the postoperative setting higher
doses between 60-66Gy are required. Thus, preopera-
tive RT seems to be more beneficial in terms of long-
term RT-associated side effects such as edema, joint
stiffness, nerve lesions or bone fractures. On the other
hand, preoperative RT is associated with a higher rates
of wound complications after surgery (35 % vs. 17 %).
This is more or less independently of the location, i.e.
shoulder, upper or lower extremity and of the histology,
which can be very heterogeneous including liposarcoma,
leiomyosarcoma, undifferentiated sarcoma or synovial sar-
coma. Thus, due to the required expertise of all disci-
plines, patients with such tumors should be treated at a
specialized sarcoma unit [1–6], since it has been shown
that treatment at a high volume center is associated
with a significantly increased survival and better func-
tional outcome [7].
Surgery is the mainstay of treatment in sarcomas and
should be evaluated in every case. If surgery with a
complete removal of the tumor is not possible, RT is a
curative alternative; local control rates range between
20–45 % [8]. Generally, function-preserving treatment
is a main goal, whereas in the past radical excisions
with compartment resections leading to a loss of function,
or amputations, were performed regularly; today, function-
preserving treatment is anticipated with complete removal
where possible, and combination with RT when necessary.
Few randomized studies are available which is mainly
due to the low incidence of soft tissue sarcomas: An
older trial compared limb amputation with a combin-
ation of extremity-conserving resection plus postopera-
tive RT; no difference in disease-free survival and overall
survival was observed [9].
Two other trials assessed postoperative RT or inter-
stitial brachytherapy, both studies showed a clear ad-
vantage for local control compared to surgery alone
[10, 11]. A large number of retrospective analyses have
confirmed the positive value of postoperative RT for
extremity sarcomas [12–23].
Today, extremity-conserving surgical treatment is pos-
sible in 80–95 % of all patients [24–28]. This requires,
however, a well-functioning interdisciplinary team con-
sisting of orthopaedic surgeons, radiation oncologists,
plastic surgeons, oncologists, pathologists and radiolo-
gists [29, 30].
In detail, two main concepts exist for the application
of RT: preoperative vs. postoperative. As in other
indications such as esophageal, pancreatic or rectal can-
cer, there are clear arguments in favor of preoperative
RT: The treatment volume is generally much smaller,
since postoperative changes as well as intraoperatively
manipulated tissue including the surgical entry channel
and scar do not need to be treated [31]. Compared to
postoperative RT, only doses of around 50 Gy are re-
quired. The smaller treatment volume together with the
lower RT dose result in lower rates of treatment-related
side effects. Moreover, tumor as well as normal tissue
oxygenation is not impaired due to postoperative scar-
ring; this leads to a higher sensitivity to radiation due to
the oxygen enhancement ratio (OER; [23]).
Another factor is the possibility of sterilization around
the tumor using preoperative RT, leading to an improved
resectability and higher rates of R0-resections [19]. This
might be explained by a thickening of the tumor capsule
which has been shown in experimental settings. On the
other hand, in spite of the clear advantages of preopera-
tive RT, higher rates of surgery-related wound complica-
tions have been shown by several groups [21, 32, 33].
A number of comparative analyses between pre- and
postoperative RT are currently available in patients with
extremity soft tissue sarcomas. A randomized prospect-
ive trial by O’Sullivan and colleagues randomized 50 Gy
preoperative RT to 66 Gy postoperative RT. In the pre-
operative group, which consisted of 94 patients, 10 pa-
tients received an additional boost up to 16–20 Gy in
cases of R1 resections. Initial data showed a slightly im-
proved local control and survival in the preoperative
group, however wound complications were 35 % com-
pared to 17 % in the postoperative RT group; function of
the extremity was comparable in both groups [13, 18].
Long term data support the beneficial risk-benefit ratio
of preoperative RT [14]. In agreement with several retro-
spective reports lower rates of long-term side effects
such as edema, fibrosis, fracture, joint stiffness or nerve
toxicity as well as better functional outcome are ob-
served [14, 15, 17, 22, 23, 32]. A meta-analysis including
1098 patients from 5 studies confirmed a higher local
control and a higher overall survival of 76 % vs. 67 % for
pre-operative RT [34]. A multi-institutional matched-
pairs analysis including 821 patients also reported an im-
proved overall survival after preoperative RT [20].
However, it has to be kept in mind that wound com-
plication rates might be higher after preoperative RT
with median complication rates of 16–35 %, depending
on the series [12, 17–19, 21, 32, 35]. The rate of wound
complications is dependent on RT dose, patient age, co-
morbidities, tumor and resection volume as well as
tumor location [18, 21, 32, 36]: For example, patients
with wound complications generally have a much larger
resection volume than those without complications
(919 cm3 vs. 456 cm3) [33].
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Regarding the RT technique, 3D-conformal RT was
standard over many years. Modern techniques such as
intensity modulated radiotherapy (IMRT) offer im-
proved dose conformality even for long and complex
shaped volumes. Treatment planning comparisons
analyzing 3D vs. IMRT could show that dose coverage
as well as reduction of dose to normal tissue (bone,
soft tissue) are better with IMRT [37–39]. Thus, since
the implementation of IMRT for the treatment of soft
tissue sarcomas, positive results were reported [40].
With helical IMRT as Tomotherapy© dose distribu-
tions often are even more conformal, longer volumes
can be treated, and the treatment machine offers on-
line MV-CT imaging for position verification. Early re-
ports on Tomotherapy© for sarcomas reported
excellent results as well as improved sparing of normal
tissue [41–44]. For daily repositioning image-guidance
as well as positioning devices are necessary. For ex-
tremity tumors, positioning inaccuracies of 1 cm or
more have been observed [45]. This can be compen-
sated by adequate treatment volumes as well as IGRT
approaches. The improvements of RT techniques en-
able the radiation oncologist to reduce and adapt
treatment volumes. For soft tissue sarcomas, in the
past, uncertainties in positioning as well as in target
volume definition depending e.g. on insufficient im-
aging have led to very large safety margins of ≥ 5 cm
proximal/distal and 2 cm circumferentially around the
visible tumor volume [31, 38, 45, 46]. Since optimized
imaging including magnetic resonance imaging (MRI)
as well as CT or PET-diagnostics are available, these
safety margins can be reduced and IGRT approaches
assure high precision of treatment delivery. Results
from brachytherapy series have shown that local dose
application to the tumor with small margins of 1–2 cm
are excellent with local control rates of 79–87 (−100) %
[10, 40, 47–50]. The main factor, however, is exact defin-
ition of the target volume and precise dose delivery.
Since complication rates are dependent on the irradi-
ated volume, the rationale for smaller safety margins
is an optimization of the risk-benefit ratio [33, 51];
initial clinical data on IMRT for soft tissue sarcomas
of the extremity have shown local control of 96 %
at 3 years with small margins of 2 cm [52]. Intra-
operative Radiotherapy (IORT) or brachytherapy can
offer an enhanced therapeutic ratio: With both tech-
niques local dose escalations directly to the target tissue
are possible, without irradiation of large areas of nor-
mal tissue.
For neoadjuvant RT, doses of 50 Gy have been estab-
lished, however, in some cases incomplete tumor resec-
tion with R1 margins requires individualized approaches.
It has been shown that local dose escalation as a boost
treatment up to 16–20 Gy with conventional fraction-
ation can be performed, however, series from the litera-
ture show controversial results [18, 53].
Combination of percutaneous RT (40–50 Gy) and a
brachytherapy boost (15–32 Gy) has been reported to be
superior to percutaneous RT or brachytherapy alone
[25, 49, 54–58]. Thus, combination treatments are con-
sidered as optimal for soft tissue sarcomas with positive
resection margins [29, 59].
Fig. 1 shows the study diagram of the PREMISS Study
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Rationale for the PREMISS study
Since the techniques of RT have been improved over the
last decades, novel concepts for the treatment of soft tis-
sue sarcomas are possible. This includes IGRT approaches
with reduced safety margins to improve the therapeutic
window in terms of reduction of long-term side effects.
Since theoretical advantages of IMRT/IGRT in this patient
population have been shown, and initial clinical data con-
firm this hypothesis, a prospective evaluation of preopera-
tive IMRT/IGRT is necessary. Thus, reduction of safety
margins around the visible tumor on MRI of 3 cm longi-
tudinally and 1.5 cm circumferentially is possible based on
previously published data [16]. For optimal surgical treat-
ment, three treatment paths are defined for optimal surgi-
cal results.
Since in < 30 % of all patients treated with function
and extremity preserving RT a R1 resection is present,
local dose escalation in analogy to the randomized trial
by O’Sullivan is part of this PREMISS trial.
The aim of the trial is to demonstrate that using mod-
ern IMRT/IGT and reduction of safety margins, postop-
erative wound complications can be reduced.
Endpoints of the study
The primary endpoint is the hypothesis that with pre-
operative IMRT/IRGT using small safety margins in
combination with local dose escalation with brachyther-
apy in the R1 situation a wound complication rate of
20 % can be achieved.
Thus, the rate of wound complications up to 90 days after
surgery is scored. Wound complications are defined as
1. any surgery for wound treatment requiring local or
general anesthesia including debridement, operative
drainage, secondary or repeated wound closure
including rotational plastic, any free tissue transfer
or skin transplantations exceeding the procedures
included into the protocol
2. invasive procedures without anesthesia, e.g. 3 x
aspiration of seroma
3. in-patient wound treatment e.g. intravenous
antibiotics
4. <90 days treatments with wound dressing materials
Secondary endpoints of the study are determination of
R0-resections, local control, metastases-free survival,
overall survival, as well as acute and late toxicities of RT.
This includes rates of extremity preservation, function of
the extremity as well as quality of life (QOL).
Study design
The trial is designed as a prospective, monocentric clin-
ical phase II trial. The study design is depicted in Fig. 1.
Treatment planning for preoperative RT
The extremity will be positioned in a stable and reprodu-
cible position using vacuum mats or mask material as ne-
cessary. For the planning CT all scars are to be marked
with wire. If necessary, bolus material is added and fixed
in a reproducible manner.
Treatment planning is based on a CT with 3 mm slice
thickness, including the visible tumor and the adjacent
joint regions, at least 20 cm beyond the visible tumor.
Fusion with MRI is performed within the treatment
planning system. MR imaging should include coronal T2
stir, axial T2 with and without contrast, T1 stir with con-
trast enhancement.
Target Volume definition
The treatment volumes are defined on the planning CT
including the following volumes:
– primary tumor (PT): macroscopic tumor on
contrast-enhanced MRI
– gross tumor volume (GTV): PT plus surrounding
pseudo capsule, i.e. edema and edematous changes
tissue including tumor cell contamination
– clinical target volume (CTV): GTV plus safety
margins – 1 cm in lateral and ventro-dorsal
direction, as well as 2.5 cm in proximal-distal
direction. Natural borders are respected, i.e. skin or
non-infiltrated bony structures as well as uninvolved
compartments.
– planning target volume (PTV): CTV plus a
circumferential safety margin of 0.5 cm.
Additionally, all relevant organs at risk (OAR) and
normal tissue structures are contoured.
Treatment technique and dose prescription
The treatment is performed with helical IMRT on the
Tomotherapy HiArt System© or with RapidArc© IMRT
as available. All treatments are performed with 6MV-
photons and daily online CT-based IGRT.
A dose of 50 Gy in 2 Gy single fractions (5 fractions per
week) is prescribed to the median in accordance with ICRU
83, with D50% = 50.0 Gy. At least 95 % of the PTV must re-
ceive 95 % of the prescribed dose, i.e. D95% > 47.5 Gy.
Surgical treatment
Surgery is planned 5–6 weeks after completion of neoad-
juvant RT. Re-staging including MRI as well as CT of the
thorax is planned 4 weeks after RT. PET-examinations or
any other imaging can be performed as required clinically.
If possible, the tumor will be resected surrounded by a
layer of healthy tissue „en bloc“ in terms of an onco-
logical radical resection ("wide/radical resection"). The
resection entry channel from the diagnostic biopsy has
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to be included completely into the resection including
the skin. An incomplete or reductive surgery is to be
avoided. Reconstructive surgery for function preserva-
tion is anticipated. Curative approaches are the primary
goal in situations when function and extremity preser-
vation is not feasible.
The resection specimen must be clipped and marked
so that correct anatomical reconstruction and correl-
ation with imaging is possible. The surgeon will clip
areas of potential incomplete resection on the resected
tissue as well as in the tumor bed.
In cases of lymph node involvement on re-staging exami-
nations in the area of the lymphatic spread of the tumor
lymphadenectomy is performed. In cases of lung metastases
after neoadjuvant RT or at the time of re-staging local con-
trol is still a priority, thus tumor resection is performed.
Thereafter, any other measures necessary are taken, such as
resection of lung lesions, chemotherapy, RT or other.
In cases of initial complete resection of the tumor dir-
ect closure of the wound is performed (Track A). If in-
traoperative rupture of the tumor occurs or if indication
for hypobaric treatment or plastic surgery is present,
vacuseal will be brought into the resection cavity and
the wound is closed secondarily (Track B and C).
Within 5 days after tumor resection results of the
pathological evaluation are available.
If the tumor is resected completely (R0), vacuseal is re-
moved and the wound is closed (track B), if necessary with
plastic surgery. If pathology reveals R1 status, secondary
resection should be evaluated. If this is not possible with a
function-preserving approach, local brachytherapy treat-
ment in the resection cavity is performed. Thereafter, the
wound is closed.
Pathology assessment
For precise pathological evaluation precise orientation
of the resected specimen is necessary, thus, it is recom-
mended that a pathologist is present at the time of
tumor resection. Classification of tumor resection mar-
gins is of high importance since the indication for local
boost dose escalation is dependent on this result. Boost
treatment should be performed on day 6–8 after resec-
tion. Pathological classification should therefore be per-
formed within 5 days after surgery and resection margins
(R0, R1, Rx) have to be communicated to the orthopaedic
surgeon and the radiation oncologist.
Besides resection margins, tumor grading as well as fur-
ther immunohistochemical stainings for exact pathological
diagnosis will be performed. The tumor will be measured
in all dimensions (in cm). Response to RT according to
the established pathological protocol for osteosarcomas
according to Salzer-Kuntschik will be evaluated [60]. Vital
tumor cells will be evaluated as established also for osteo-
sarcomas [61].
Local dose escalation
In cases of R1 resection brachytherapy is anticipated in
the 2. postoperative week. Brachytherapy catheters are
implanted into the tumor bed depending on the size and
location of the lesion.
Treatment planning is based on 3D-CT imaging with
3 mm slice thickness as well as the most recent MRI
available.
The CTVBRT for the brachytherapy application in-
cludes the R1-area plus a 5 mm safety margin, or a boost
the complete resection cavity plus 5 mm safety margin.
No additional PTVBRT is added since the catheters are
implanted directly into the target area.
Brachytherapy is performed using Iridium-192 High-
Dose Rate (HDR)-afterloading. A dose of 12–15 Gy with
3 Gy single doses and 2 fractions per day (≥6 h between
fractions) with D90% for the CTV/PTVBRT is applied.
Further evaluations
To characterize the effectivity of neoadjuvant IMRT/
IGRT for extremity sarcomas, the following evaluations
will be performed:
– comparison of “conventional safety margins” and
reduced safety margins within the protocols on
treatment planning comparisons and calculation
of dose reduction to normal tissue
– evaluation of tumor response on MRT as well
as statement on resectability of the operating
orthopaedic surgeon prior to resection based
on imaging only
– histopathological characterization of the tumor and
tumor response to treatment
– correlation of tumor response with outcome and
prognosis.
Inclusion criteria:
 histologically confirmed and imaging defined soft
tissue sarcoma of the extremities
 AJCC-Stage II or III (without T1a-tumos, no N1)
 primary or recurrent tumor
 after biopsy or previous R2 resection
 based on imaging, „primary resectability“ or potential
resectability after neoadjuvant RT must be present
 age ≥ 18 years
 ECOG Performance Status 0–2
 informed consent
Main exclusion criteria
 extraskeletal tumors of the Ewing-/PNET-group
 extraskeletal osteo- or chondrosarcoma
 aggressive fibromatosis (desmoid tumors)
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 dermatofibrosarcoma protuberans
 presence of lymph node metastases (N1) or distant
metastases (M1)
 expected survival < 1 year
 pregnancy, adequate contraception until 3 months
after RT
 severe comorbidities impairing study treatment
 severe wound infections or recurrent skin infections
 known positive HIV-Status
 surgery of the primary tumor or chemotherapy
within the last two weeks prior to study treatment
 persistent toxicity of other tumor treatments in the
treatment region
 simultaneous chemotherapy, targeted therapy or
experimental tumor therapy
 previous RT in the treatment region
 medication with steroids or immuno-suppressants
Follow-up
All patients are seen for a first follow-up visit 2 weeks after
wound healing is completed, thereafter every 3 months
during the first 2 years. The endpoints of the study are
evaluated in detail during the first (2 weeks) and second
(3 months) follow-up.
Functional outcome and QOL are documented prior
to treatment and at year 1 and 2.
Treatment response and efficacy will be scored accord-
ing to the RECIST 1.1 criteria.
Sample size calculation
A total patient number of 50 with an expected 20 % rate
of wound complications was calculated for the study; the
intent to treat (ITT) collective includes all patients in-
cluded into the trial which signed informed consent and
were allotted a patient study number. The per proto-
col collective (PP) includes only those patients, whose
study treatment was applied completely without any
severe protocol deviations.
Analysis for the primary and secondary endpoints are
performed on the ITT collective, and re-evaluated in the
PP group. The primary endpoint is the rate of wound
complications 3 months after wound closure, including
the 95 % confidence interval. The secondary endpoints are
analyzed with an explorative approach. The rate of wound
complications per treatment track is evaluated as means
including the 95 % confidence interval. Survival rates are
determined using the Kaplan-Meier Method.
Discussion
Neoadjuvant RT is an established treatment approach
for extremity sarcomas, showing beneficial results com-
pared to postoperative treatment. A major downside are
increased rates of wound complications compared to
postoperative RT. However, with modern RT approaches
such as IMRT and IGRT, treatment precision is opti-
mized with daily image guidance.
In the past, large safety margins were necessary to pro-
vide optimal oncological treatment, however, these safety
margins most probably also contributed to the high rates
of side effects since large amounts of normal tissue were
exposed to RT.
The use of modern techniques enables the radiation
oncologist to deliver precise RT doses, therefore margins
around the tumor can be reduced which leads to sparing
of normal tissue.
The present study protocol prospectively evaluates
the use of IMRT/IGRT as neoadjuvant RT in patients
with soft tissue sarcomas of the extremity with the pri-
mary endpoint wound complications, which is the
major concern with this treatment sequence. Besides
complications rates, local control rates and survival
rates, as well as QOL and functional outcome as well
as treatment response parameters (imaging and path-
ology) are part of the protocol. The data of the present
PREMISS study will enhance the current literature and
support the hypothesis that neoadjuvant RT with
IMRT/IGRT offer an excellent risk-benefit ratio in this
patient population.
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